Second trimester maternal serum screening for Down's syndrome is a considerable advance over screening using maternal age alone. This paper reviews the performance using two (double test), three (triple test), and four (quadruple test) biochemical markers. The medical benefits and financial cost effectiveness of screening using the triple and quadruple tests are compared.
Rational judgments about which markers should be included in a multimarker screening test are needed. The costs and benefits should be compared, both with respect to the medical benefits (increasing detection rates and reducing the proportion of fetal losses through amniocentesis for each Down's syndrome pregnancy diagnosed) and the financial costs (particularly the cost for each case diagnosed). If the use of an additional marker is medically more beneficial, it should, of course, be considered as an alternative to existing practice. If the financial cost for each unit of outcome is also reduced, the decision is straightforward. There is an obligation to introduce the improvement, provided that the total expenditure is affordable. If the extra benefit is more expensive for each unit of outcome, the improvement may still be adopted, but discussion would be needed to determine whether the benefit is worth the extra financial cost.
based on age specific rates of Down's syndrome at birth." The proportion of those pregnancies identified through antenatal diagnosis and terminated is also shown"; in 1991 this proportion was 36%. Table 1 shows the results from four demonstration projects which used the triple test (AFP, uE), hCG).6-9 Together, these projects confirmed prospectively the performance of serum screening as determined retrospectively in studies using frozen serum samples, and showed that 78% of women with positive screening tests took up the offer of an amniocentesis, and that the odds of such women having an affected pregnancy was 1 to 35.
Which screening test?
Screening can now be offered as the double test using AFP and hCG (either total hCG or free~-hCG), the triple test using AFP, uE), and hCG (again with either total or free~ hCG), or the quadruple test using AFP, uE), the free (X subunit of hCG, and either total or free~-hCG. Tables 2 and 3 show the performance of Down's syndrome screening at 15-22 
Background
Until the end of the last decade, antenatal screening for Down's syndrome was carried out by offering all women above a specified age a diagnostic amniocentesis. Some centres combined (X fetoprotein (AFP) measurements with maternal age to improve the performance of screening, but even this resulted in the detection of no more than about 35% of all affected pregnancies among the 5% of women at highest risk who would require amniocentesis for the confirmatory diagnosis. With the introduction of measurement of unconjugated oestriol (uE)) and human chorionic gonadotrophin (hCG), together with AFP, the performance of screening improved considerably, so that about 60% of affected pregnancies could be identified by diagnostic testing in the 5% of women at highest risk.' 2 Figure 1 shows the proportion of health districts and boards in Britain in 1991 and 1992 offering different methods of screening." In 1992 about two thirds of health districts and boards had some form of serum screening -over 50% using more than one biochemical marker. Figure 2 shows the expected birth prevalence of Down's syndrome in England and Wales from 1974 to 1991 in the absence of antenatal diagnosis and selective abortion Table 1 Results from four demonstration projectsr" ·Gestational age estimated by time since the first day of the last menstrual period. tGestational age based on ultrasound measurement of the biparietal diameter or crown rump length. 
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weeks' gestation according to the screening test and the method of estimating gestational age. Table 2 shows this as the detection rate for  a 5% false positive rate and table 3 shows it as the false positive rate for a 60% detection rate. The combinations of tests are those with the best screening performance, given the inclusion of AFP which is retained because of its use in screening for open spina bifida. The performance of the screening tests is derived using data from a prospective study in which antenatal serum was routinely stored. Subsequently stored serum samples from 77 pregnancies with Down's syndrome and 385 matched controls were analysed. Parameter estimates of the screening variables in white subjects with Down's pregnancies and unaffected pregnancies were used.' Tables 2 and 3 lead to a number of conclusions.
Firstly, performance of the double test (or the triple test) is similar whether total or freẽ -hCG is used. Secondly, with the quadruple test there is an advantage in using free~-hCG rather than total hCG (though the effect is small), mainly because there is less correlation between free ex-hCG and free~-hCG than there is between free ex-hCG and total hCG so that measurement of the two subunits separately provides .relatively independent measures of risk of a Down's syndrome pregnancy.
Thirdly, adding uE] (triple testing instead of double) only slightly increases the detection for a given false positive rate (or a decrease in false positive rate for a given detection rate) when gestational age is estimated using dates, but the increased detection is greater if gestation is estimated using an ultrasound scan. The extra advantage of uE] if gestational age is estimated by scan arises because the concentration of uE] changes more with gestational age than does the concentration of the other markers, so uE] is the marker that stands to gain most from improvements in the method of estimating gestation. For example, with the addition of uE], and with gestational age estimated by scan, the detection rate increases from 58% to 67% at a 5% false positive ratean increase of nine percentage points in detection. Alternatively, the false positive rate declines from 5·7% to 3% (about one half) at a 60% detection rate.
Fourthly, the quadruple test increases the detection rate by an extra 6% above that of the triple test at a 5% false positive rate, or decreases the false positive rate by about an extra 1-2% at a 60% detection rate, representing a large proportionate reduction in the false positive rate (about one third). The best performance is obtained using the quadruple test with a routine scan examination to estimate gestational age; such screening can detect 72% of affected pregnancies with a false positive rate of5%. Tables 4 and 5 show the performance of the double, triple, and quadruple tests according to risk cut off level. • Detection rate = proportion of affected pregnancies with risk greater than or equal to cut off (positive result), t False positive rate = proportion of unaffected pregnancies with risk greater than or equal to cut off (positive result).
• Detection rate = proportion of affected pregnancies with risk greater than or equal to cut off (positive result).
t False positive rate~proportion of unaffected pregnancies with risk greater than or equal to cut off (positive result). Medical considerations and financial costs of screening using different tests Figure 3 shows the cost for each case of Down's syndrome diagnosed when the double, triple, and quadruple screening tests are used. The bottom half of the figure shows the corresponding false positive rate at each level of detection. At all levels of detection the addition of uE 3 (triple test versus double test) is associated with a lower false positive rate (and therefore less fetal losses due to amniocentesis). Table 6 shows the fetal loss rates attributable to amniocentesis for each case diagnosed. These increase with detection rate, but are lower when gestational age is estimated by scan rather than dates, and lower with the triple test than the double test. At detection rates greater than about 60% the financial cost for each case of Down's syndrome diagnosed is also lower for the triple test than for the double test (fig 3) .
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At all levels of detection the quadruple test is associated with a lower false positive rate and lower fetal loss rate, and at detection rates greater than about 65% it is also financially more cost effective than the triple test. This holds whether gestational age is measured by dates or scan. If the false positive rate were kept constant at 5%, the cost per case diag-nosed would be similar whatever test were used (£32 000 per test with gestational age estimated by scan, and £34 000, £36 000, and £35 000 respectively for the double, triple, and quadruple tests with gestational age estimated by dates), though of course the costs for every 1000 women screened would be higher (costs £18 000, £21000, and £22 000 respectively for the double, triple, and quadruple tests).
The financial cost of the serum test includes the cost of the biochemical analysis, interpretation of the tests, professional education, monitoring, provision of information to patients, and counselling women with positive screening results. The cost of diagnosis consists of the costs of amniocentesis and karyotyping. The cost of performing a routine dating scan is not included in our analysis, as increasingly, this antenatal investigation is being offered routinely for all women. The cost estimates are those used previously," and the additional cost of serum screening with the free (X subunit of hCG is taken to be £1.50. These costs are summarised in the legend to fig 3.
Conclusions
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• The fetal loss rate attributable to amniocentesis was taken to be 1'%. 11 fetal loss due to amniocentesis compared with the double and triple tests. This enables higher levels of detection to be attained while keeping false positive rates manageable. At detection rates above about 65% the quadruple test is also financially cost effective as the cost per Down's syndrome pregnancy diagnosed is less than with the alternative screening methods considered. If the screening programmes were all carried out at a 5% false positive rate and gestational age estimated by scan, the quadruple test would achieve detection rates five percentage points higher than the triple test, or fourteen percentage points greater than the double test (see table 2 ). Costs per case diagnosed are identical whichever screening test is used at this false positive rate. As financial costs per unit of outcome are not increased, and the medical benefits are increased, the Wald, Watt quadruple test is the screening method of choice.
